MarketInOut Stock Screener Log In | Sign Up

Dianthus Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Dianthus Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization4,503.4 mln
Float46.51 mln
Earnings Date11/05/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

1.02
Highly suspicious

1-Year Forecast

139.06
Transformational upside

Relative Strength

95 / 100
Top performer

Debt / Equity

0.00
Debt-free

Pre-Tax Margin

-10,097%
Severely loss-making

Business Description

Dianthus Therapeutics is a New York-based company founded in 2019 that focuses on treating serious autoimmune conditions through cutting-edge medical research. The company is advancing two promising drug candidates: one that precisely targets a key part of the immune system's complement pathway, and another that works in two ways at once to dial down harmful immune activity in certain white blood cells. Together, these treatments aim to offer new hope to patients whose immune systems attack their own bodies.

Key Fundamentals

EPS-4.24
ROE-25.87
RPS0.04
ROIC-129
ROA-24.68
EBITDA, mln-192
EV / EBITDA-19.19
EV / EBIT-19.15
Revenue, mln1.90
EV / Revenue1,934

Quote Details

Last 82.38
Change -0.32 (-0.39%)
Open 81.29
Volume 496,892
Turnover 40,933,960
Average Volume 918,189

Financial Ratios

Pre-Tax Profit Margin-10,097
Leverage Ratio1.04
Current Ratio26.10
Price / Book3.72
Price / Tangible Book3.72
Debt / Equity0.00
Price / Sales1,988

Financial Strength

Altman Z-Score64.39
Piotroski F-Score 3 / 9
Beneish M-Score1.02
1-Year Target Price139.06
Short Ratio9.16
Short % of Float18.43

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 7.29% 91 / 100   
1 Month -6.73% 35 / 100   
2 Months -21.16% 21 / 100   
6 Months -5.77% 41 / 100   
1 Year 144% 98 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog